ALAMEDA, Calif., Nov. 1, 2006 (PRIMEZONE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company developing innovative therapies for the treatment of neurological conditions, announced today that Kenneth Chahine, Ph.D., J.D., Avigen’s President and CEO, will present at three upcoming healthcare conferences:
